Theratechnologies Inc's Competitiveness
A competitive positioning analysis and financial ratio benchmarking of Theratechnologies Inc (THTX) against its publicly traded competitors: sales growth, net income, profitability, valuation and market share, plus each peer's market capitalization, revenue, income and employees. Free below: the top 5 peers. Subscriber access adds the full competitor list and CSV downloads.
Key Findings: Theratechnologies Inc vs Its Competitors
- TTM: Trailing 12-month revenue of 86M vs 622,678M combined for its competitors (0.0% combined share).
- Trending: Latest-quarter revenue run-rate is accelerating (+300.0% annualized vs trailing 12 months), vs accelerating (+64.4%) for its tracked peer group.
- Growth: Theratechnologies Inc generated 5.0% revenue growth year over year in Q4 2024, vs 8.7% for its competitors combined.
- Profitability: Its -9.7% net margin compares with 15.4% for the peer group.
- Peer revenue share: Theratechnologies Inc accounted for 0.0% of combined revenue among its tracked peer group, up from 0.0% a year earlier.
- Peer differentiation: Revenue per employee of $0.98M compares with $1.00M for the peer group (1.0x).
Every figure above is sourced and cited in detail further down this page (Market Structure, Profitability & Cost Structure, Productivity vs Peers).
THTX Sales vs. its Competitors, Q4 2024
Theratechnologies Inc reported revenue growth of 5.02 % year on year in Q4 2024, below its competitors' combined revenue growth of 8.72 %.
With a net margin of -9.67 %, Theratechnologies Inc reported lower profitability than its competitors (15.35 %).
Theratechnologies Inc generated 0.03 % of the combined sales of its peer group, up from 0.03 % a year earlier.
API endpoints for this dataset
Theratechnologies Inc vs. its Competitors, Q4 2024
Revenue growth, year on year
Net margin
Revenue run-rate vs trailing 12 months
TTM net margin
TTM = trailing twelve months. Run-rate annualizes the latest quarter (×4) and compares it to TTM. In millions of $. High-Confidence Competitors are named as a competitor directly in Theratechnologies Inc reports; Similar-Size Competitors are the closest peers by market-cap rank within the same industry; Similar Growth & Profitability Competitors are the closest peers by combined revenue growth, operating margin and ROIC, all independent of the competitor list.
TTM revenue, latest-quarter run-rate and net income/margin benchmarked across Theratechnologies Inc and its 4 competitor groupings. Available under Commercial License.
| Entity | TTM Revenue | Rev Run-rate vs TTM |
|---|---|---|
| Theratechnologies Inc | $12,345M | +12.3% · Accelerating |
| Competitors combined | $12,345M | +12.3% · Accelerating |
TTM revenue, run-rate and net margin benchmarking across Theratechnologies Inc's competitor groups requires a Commercial License.
For context: the Major Pharmaceutical Preparations industry grew revenue 9.0% year over year, combined, vs 5.0% for Theratechnologies Inc. Theratechnologies Inc's share of combined industry revenue moved from 0.02% to 0.02%, a gain of 0.00 percentage points.
Theratechnologies Inc's Competitor Quality Breadth
Group definitions: see Methodology: Performance Group Definitions.
| Entity | Profitable | Expanding | Above Industry Growth | Distressed |
|---|---|---|---|---|
| Theratechnologies Inc | No | Yes | No | No |
| Competitors combined (80) |
Source: CSIMarket API, trailing 12 months. Altman Z-Score is not shown here: it is not populated in the underlying data for any company. Percentages are of companies in each group that report the relevant metric, not of the full group size.
THTX Stock Performance relative to its Competitors
5 Best-Performing Tracked Competitors, Trailing 12 Months
| # | Competitor | TTM Share Price Return | vs U.S.A. 500 |
|---|---|---|---|
| 1 | Regulus Therapeutics Inc | 282.9% | Outperformed |
| 2 | Prelude Therapeutics Inc | 282.9% | Outperformed |
| 3 | Silence Therapeutics Plc | 282.9% | Outperformed |
| 4 | Organon and Co | 282.9% | Outperformed |
| 5 | Viatris Inc | 282.9% | Outperformed |
TTM share price return and U.S.A. 500 outperformance for Theratechnologies Inc's best-performing competitors requires a Commercial License.
Source: CSIMarket API, trailing 12 months.
Theratechnologies Inc's Comment on Competition and Industry Peers
Publicly Traded Peers of Theratechnologies Inc
Revenue and income for trailing 12 months, in millions of $, except employees| Company | Market Cap | Revenues |
|---|---|---|
 Theratechnologies Inc |
167.34 | 85.87 |
 Eli Lilly And Company |
1,266,984.14 | 86,462.00 |
 Johnson and Johnson |
690,566.66 | 99,335.00 |
 Merck and Co Inc |
364,891.87 | 66,569.00 |
 Novartis Ag |
318,410.85 | 56,674.00 |
 Astrazeneca Plc |
292,094.00 | 58,739.00 |
| SUBTOTAL | 4,145,048.92 | 653,605.17 |
Sign in to see all competitors of Theratechnologies Inc .
Sources: see Methodology: Peer & Competitor Identification, Sourcing.
Updated on:
Focus of this report: publicly traded companies. Ten additional tables on Theratechnologies Inc versus competitors, including market share analysis, are in the navigation menu under Competition. To download the tables, please subscribe.
Theratechnologies Inc's Competitors Named by the Company
Competitive relationships identified from Theratechnologies Inc reports and corroborating sources, each with a basis and confidence.| Competitor | Basis | Confidence |
|---|---|---|
| TaiMed | Company report | 85% |
| Transfert Plus | Company report | 85% |
| Katana | Company report | 85% |
Company report basis, confidence, active dates and source counts for Theratechnologies Inc's named competitors require a Commercial License.
Methodology: see Methodology: Peer & Competitor Identification, Sourcing.
Theratechnologies Inc's Business Segment Mix vs Peers
Revenue by operating segment or division, as named and reported by each company. Segment names are the filer's own and are not standardized across companies. Do not assume a same-named or similarly-named segment is defined identically between two companies. Shares are of each company's own total revenue and are not required to sum to 100% (intersegment revenue, unallocated items).| Company | Largest Segment |
|---|---|
| Eli Lilly And Company | Reportable 100.00 % |
| Johnson and Johnson | Oncology 29.93 % |
| Merck and Co Inc | Pharmaceutical segment 89.95 % |
| Amgen Inc | Reportable 100.00 % |
| Vertex Pharmaceuticals Inc | Pharmaceuticals 100.00 % |
Source: operating segment revenue as reported in each company's reports (10-K/10-Q), via the CSIMarket API, leaf-level reportable segments only (parent roll-up segments are excluded where sub-segments are separately disclosed).
Sign in to see all peers for Theratechnologies Inc .
Theratechnologies Inc's Productivity vs Peers Comparison
Revenue and income per employee, trailing 12 months, in $; market cap in millions of $| Company | Market Cap | Revenue / Employee | Income / Employee |
|---|---|---|---|
| Theratechnologies Inc | 167 | 975,750 | -94,386 |
| Eli Lilly And Company | 1,266,984 | 1,729,240 | 551,594 |
| Johnson and Johnson | 690,567 | 705,504 | 114,311 |
| Merck and Co Inc | 364,892 | 887,587 | 42,267 |
| Novartis Ag | 318,411 | 752,973 | 185,566 |
| Astrazeneca Plc | 292,094 | 706,847 | 123,141 |
| PEERS TOTAL | 4,144,882 | 998,355 | 154,492 |
Sign in to see all peers for Theratechnologies Inc .
Theratechnologies Inc's Geographic Revenue Exposure vs Peers
Revenue by country/region as reported in each company's most recent report. Disclosure granularity varies by filer (some report by country, others by broad region) and is shown as disclosed.| Company | Largest Market |
|---|---|
| Eli Lilly And Company | United States 62.04 % |
| Johnson and Johnson | United States 58.90 % |
| Merck and Co Inc | EMEA 21.50 % |
| Gilead Sciences Inc | United States 76.66 % |
| Vertex Pharmaceuticals Inc | United States 63.04 % |
Source: revenue geography as reported in each company's reports (10-K/10-Q), via the CSIMarket API. Percentages are of that company's own total consolidated revenue for its most recent reported period.
Sign in to see all peers for Theratechnologies Inc .
Theratechnologies Inc's Position in Industry Market Structure
Market-capitalization share and concentration across all 491 companies in Theratechnologies Inc's industry classification, broader than the peer set above. Market cap in millions of $.Theratechnologies Inc ranks #0 of 491 companies by market capitalization in its industry, holding 0.00 % of total industry market cap. The industry's Herfindahl-Hirschman Index (HHI) is 983, indicating a unconcentrated market structure (see Methodology: Market Structure & Concentration).
| Rank | Company | Market Cap | Industry Share |
|---|---|---|---|
| 1 | Eli Lilly And Company | 1,267,410 | 23.79 % |
| 2 | Johnson and Johnson | 688,169 | 12.92 % |
| 3 | Abbvie Inc | 519,284 | 9.75 % |
| 4 | Merck and Co Inc | 364,892 | 6.85 % |
| 5 | Novartis Ag | 1,234 | 5.2% |
| 6 | Abbott Laboratories | 1,234 | 5.2% |
| 7 | Novo Nordisk A | 1,234 | 5.2% |
| 8 | Pfizer Inc | 1,234 | 5.2% |
| 9 | Astrazeneca Plc | 1,234 | 5.2% |
| 10 | Vertex Pharmaceuticals Inc | 1,234 | 5.2% |
| 0 | Theratechnologies Inc | - | 0.00 % |
Market cap and industry share for the rest of Theratechnologies Inc's industry peers requires a Commercial License.
Source: CSIMarket API (daily market-structure computation) across CSIMarket's industry classification, market capitalization as of 2026-06-08.
Theratechnologies Inc's Profitability & Cost Structure
Trailing 12-month margins from SEC-filed financials. Operating margin is compared to the Major Pharmaceutical Preparations industry median; gross margin, EBITDA margin and capital intensity are compared to the live industry average (446 companies). See the full Major Pharmaceutical Preparations industry profitability benchmarks.| Metric | Company | Industry | Difference |
|---|---|---|---|
| Gross Margin | 76.19 % | 37.93 % (avg) | +38.3 pp |
| Operating Margin | 9.52 % | industry median | +49.5 pp |
| EBITDA Margin | -4.52 % | -6.39 % (avg) | +1.9 pp |
| Capital Intensity (Capex / Revenue) | 0.00 % | 7.56 % (avg) | -7.6 pp |
Source: CSIMarket API, trailing 12 months. SG&A and R&D as a share of revenue have limited coverage as this data is backfilled and appear only where reported. Higher capital intensity is not inherently negative; it reflects the industry's asset requirements.
Theratechnologies Inc's Multi-Year Financial Trajectory
Fiscal-year revenue growth, operating margin, return on invested capital and P/E, as reported in company reports.| Metric | 2022 | 2023 | 2024 |
|---|---|---|---|
| Revenue Growth | 14.66 % | 2.13 % | 5.02 % |
| Operating Margin | -49.85 % | -13.00 % | 9.52 % |
| Return on Invested Capital | - | -110.64 % | - |
| P/E | - | - | - |
Source: CSIMarket API, fiscal-year figures. P/E is this company's own historical ratio at each fiscal year end and can swing sharply around an earnings trough: that is real, not a data error.
Theratechnologies Inc's Competitive Forces (Porter's Five Forces)
Only the forces this data can support honestly are shown; the other three are marked as such rather than guessed.| Force | Assessment | Basis |
|---|---|---|
| Competitive Rivalry | High | Industry HHI of 983 (see Industry Market Structure & Concentration above) |
| Barriers to Entry | Lower than typical for the industry | Capital intensity (capex / revenue) of 0.00 % vs industry average 7.56 % (see Profitability & Cost Structure above) |
Note: see Methodology: Porter's Five Forces. Supplier power and buyer power are covered on Theratechnologies Inc's dedicated Suppliers and Customers pages, not here.
Theratechnologies Inc's Industry Attractiveness & Competitive Strength
See Methodology: GE/McKinsey Matrix for how the two axes are built.
Theratechnologies Inc falls in the Low attractiveness / Medium strength cell: Harvest.
Source: CSIMarket API, trailing 12 months. Each axis score is a simple 1(low)/2(medium)/3(high) average across its three inputs -- a transparent, disclosed simplification, not a validated academic scoring model.
Theratechnologies Inc's SWOT
Every point below is a fixed rule applied to a metric already shown elsewhere on this page (Market Structure, Profitability, Valuation, Run-Rate, Stock Performance, Quality Breadth) not an independent strategic assessment. A blank quadrant means no rule was met, not that none apply.Strengths
- Operating margin 49.5 points above the industry median.
- Latest-quarter revenue run-rate is accelerating (+300.0% annualized vs trailing 12 months).
- Outperforming the U.S.A. 500 over the trailing 12 months.
Weaknesses
No rule matched.
Opportunities
- A meaningful share of competitors (52.50 %) show financial-distress signals, a possible opening to gain share.
Threats
No rule matched.
Methodology: see Methodology: SWOT Analysis.
Theratechnologies Inc's Financial Strength vs Peers Comparison
Quick ratio, working capital, debt to equity and asset turnover, trailing 12 months| Company | Quick Ratio | Working Capital | Debt / Equity |
|---|---|---|---|
| Theratechnologies Inc | 0.59 | 1.19 | - |
| Eli Lilly And Company | 0.16 | 1.44 | 1.44 |
| Johnson and Johnson | 0.36 | 1.04 | 0.60 |
| Merck and Co Inc | 0.40 | 1.46 | 1.01 |
| Novartis Ag | 0.42 | 1.12 | 0.02 |
| Astrazeneca Plc | 0.19 | 0.94 | 0.51 |
Sign in to see all peers for Theratechnologies Inc .
Quick ratio = cash / current liabilities; working capital ratio = current assets / current liabilities; asset turnover = revenue / total assets. Peers in the Blank Checks industry are excluded.
Theratechnologies Inc's Revenue and Income Growth vs Peers
Quarterly revenue and net income growth, year over year and quarter over quarter| Company | Period | Revenue Y/Y | Income Y/Y |
|---|---|---|---|
| Theratechnologies Inc | Q4 2024 | +5.0 % | - |
| Eli Lilly And Company | Q3 2026 | +38.6 % | +15.6 % |
| Johnson and Johnson | Q3 2026 | +5.9 % | -95.9 % |
| Merck and Co Inc | Q2 2026 | +5.1 % | - |
| Novartis Ag | Q4 2025 | +9.6 % | +17.0 % |
| Astrazeneca Plc | Q4 2025 | +8.6 % | +45.3 % |
| PEERS TOTAL | +10.2 % | -1.0 % |
Sign in to see all peers for Theratechnologies Inc .
Growth is shown only where both periods are positive. Peers in the Blank Checks industry are excluded.
Theratechnologies Inc's Peers' Costs of Sales and Capital Expenditures
Context for revenue growth: peer costs and capex, year over year and quarter over quarter| Company | Period | Costs Y/Y | Capex Y/Y |
|---|---|---|---|
| Theratechnologies Inc | Q4 2024 | +15.7 % | - |
| Eli Lilly And Company | Q3 2026 | +30.7 % | +52.2 % |
| Johnson and Johnson | Q3 2026 | +10.9 % | +17.7 % |
| Merck and Co Inc | Q2 2026 | +23.6 % | +16.9 % |
| Novartis Ag | Q4 2025 | +18.3 % | +13.3 % |
| Astrazeneca Plc | Q4 2025 | +11.2 % | +46.0 % |
Sign in to see all peers for Theratechnologies Inc .
Theratechnologies Inc's Returns and Turnover vs Peers
ROA, ROI and ROE (trailing 12 months), receivables and inventory turnover| Company | ROA | ROI | ROE |
|---|---|---|---|
| Theratechnologies Inc | - | - | - |
| Eli Lilly And Company | 21.24% | 32.00% | 83.65% |
| Johnson and Johnson | 8.06% | 10.53% | 19.55% |
| Merck and Co Inc | 2.42% | 3.24% | 6.59% |
| Novartis Ag | 12.59% | 12.62% | 30.00% |
| Astrazeneca Plc | 8.97% | 19.67% | 21.00% |
Sign in to see all peers for Theratechnologies Inc .
ROA = net income / total assets; ROI = net income / investments; ROE = net income / equity; turnover ratios use trailing 12 month revenue (receivables) and cost of sales (inventory).
Theratechnologies Inc's Valuation vs Peers
P/E, price to sales, PEG, price to cash flow and price to book| Company | P/E | Price / Sales |
|---|---|---|
| Theratechnologies Inc | - | 1.95 |
| Eli Lilly And Company | 46.04 | 14.65 |
| Johnson and Johnson | 42.67 | 6.95 |
| Merck and Co Inc | 119.14 | 5.48 |
| Novartis Ag | 22.77 | 5.62 |
| Astrazeneca Plc | 28.59 | 4.97 |
| PEERS AVERAGE | 40.99 | 6.34 |
Sign in to see all peers for Theratechnologies Inc .
P/E = price / diluted EPS (trailing 12 months); PEG = P/E divided by EPS growth; the average row divides the peers' combined market cap by their combined income, sales, cash flow and equity.